Schizophrenia Drugs Market with COVID-19 Impact Analysis, by Therapeutic Class (Second Generation, Third Generation, and Other), by Treatment (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Schizophrenia Drugs Market size was valued at USD 7,579.21 Million in 2022, expanding at a CAGR of 5.81% from 2023 to 2030.
Schizophrenia drugs are pharmacological chemicals that are used to treat the symptoms of schizophrenia, a complicated mental condition marked by disordered thoughts, feelings, and perceptions. These medications primarily target neurotransmitter imbalances in the brain, specifically dopamine and serotonin, in order to reduce hallucinations, delusions, disordered thinking, and social disengagement. Schizophrenia medications attempt to improve the quality of life for those suffering from the condition by reducing symptoms and increasing functional recovery, frequently as part of a complete treatment plan that includes counseling and psychological support.
Schizophrenia Drugs Market- Market Dynamics
- Increasing prevalence of schizophrenia and associated disorders
The increased frequency of schizophrenia and related illnesses, along with an aging population that is more vulnerable to late-onset schizophrenia, is the primary driver driving market expansion throughout the projection period. According to the WHO, schizophrenia will affect 24 million people globally by 2022. Furthermore, with the aging of people in general, the figure is anticipated to rise further. The increased prevalence of schizophrenia is driving the need for effective treatment, moving the schizophrenia medications market forward. As more people are diagnosed, there is a larger demand for pharmacological treatments to control symptoms, which is fueling research, innovation, and market development in this sector.
Schizophrenia Drugs Market- Key Insights
- As per the analysis shared by our research analyst, the global Schizophrenia Drugs market is estimated to grow annually at a CAGR of around 5.81% over the forecast period (2023-2030)
- The Schizophrenia Drugs industry is projected to grow at a significant rate due to the increasing prevalence of schizophrenia and associated disorders
- Based on therapeutic class segmentation, second generation was predicted to show maximum market share in the year 2022
- Based on treatment segmentation, injectable was the leading type in 2022
- Based on distribution segmentation, hospital pharmacies was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Schizophrenia Drugs Market- Segmentation Analysis:
The Global Schizophrenia Drugs Market is segmented on the basis of Therapeutic Class, Treatment, Distribution Channel, and Region.
The market is divided into categories based on therapeutic class: Second Generation, Third Generation, and Other. The Second-generation antipsychotics segment is expected to grow over the forecast period, owing to the factors such as the increased frequency of mental health illnesses such as schizophrenia, particularly effective in treating symptoms such as delusions and hallucinations in people with schizophrenia.
The market is divided into categories based on treatment: oral and injectable. The injectable segment dominates the market. Injectable-based schizophrenia medicines, particularly long acting injectables (LAIs), are among the most sophisticated kinds of therapy. Long-acting injectables frequently aid in the elimination of the drawbacks associated with oral schizophrenia therapy. Some of the advantages of the injectable include improved adherence to treatment regimens, reduced relapses, and the avoidance of irreversible cognitive and neurological impairment in patients.
Schizophrenia Drugs Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold a significant market share the market owing to the growing incidence of schizophrenia and associated mental disorders in the general population, the presence of robust healthcare infrastructure rising geriatric population, high spending on healthcare, and the presence of major market players. Schizophrenia affects about 1.5 million adults annually in the United States, in accordance to the National Alliance of Mental Illness (NAMI) update from June 2022. As a result, it is anticipated that there will be a demand for schizophrenia drugs in the area, which will drive growth in the North American market under study.
Schizophrenia Drugs Market- Competitive Landscape:
Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in 2022, In order to conduct research, develop, and market novel dopamine receptor modulators for the potential treatment of neuropsychiatric illnesses, AbbVie and Gedeon Richter have engaged into a new co-development and license agreement.
Recent Developments:
- In May 2023, UZEDY, a brand-new medication for the treatment of schizophrenia, received FDA approval. UZEDY is a medication produced by Teva Pharmaceutical Industries, Ltd. that gradually releases the active component, risperidone, over the course of one to two months using copolymer technology.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL SCHIZOPHRENIA DRUGS MARKET KEY PLAYERS
- Vanda Pharmaceuticals
- Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
- Sumitomo Dainippon Pharma
- Recordati Rare Diseases
- Pfizer
- Otsuka Pharmaceutical
- Novartis
- Johnson & Johnson (Janssen Pharmaceuticals)
- Intra-Cellular Therapies
- Lundbeck A/S
- Eli Lilly and Company
- Bristol Myers Squibb
- AstraZeneca
- Allergan (now part of AbbVie)
- Alkermes plc
GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS
- Second Generation
- Third Generation
- Other
GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT
- Oral
- Injectable
GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
Rest of MEA
TABLE OF CONTENT
1. Schizophrenia Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Schizophrenia Drugs Market Snippet by Therapeutic Class
2.1.2. Schizophrenia Drugs Market Snippet by Treatment
2.1.3. Schizophrenia Drugs Market Snippet by Distribution
2.1.4. Schizophrenia Drugs Market Snippet by Country
2.1.5. Schizophrenia Drugs Market Snippet by Region
2.2. Competitive Insights
3. Schizophrenia Drugs Key Market Trends
3.1. Schizophrenia Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Schizophrenia Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Schizophrenia Drugs Market Opportunities
3.4. Schizophrenia Drugs Market Future Trends
4. Schizophrenia Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Schizophrenia Drugs Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Schizophrenia Drugs Market Landscape
6.1. Schizophrenia Drugs Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Schizophrenia Drugs Market – By Therapeutic Class
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutic Class, 2022 & 2030 (%)
7.1.2. Second Generation
7.1.3. Third Generation
7.1.4. Other
8. Schizophrenia Drugs Market – By Treatment
8.1. Overview
8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
8.1.2. Oral
8.1.3. Injectable
9. Schizophrenia Drugs Market – By Distribution
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution, 2022 & 2030 (%)
9.1.2. Hospital Pharmacies
9.1.3. Retail Pharmacies
9.1.4. Online Pharmacies
10. Schizophrenia Drugs Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Schizophrenia Drugs Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Schizophrenia Drugs Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Schizophrenia Drugs Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Schizophrenia Drugs Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Schizophrenia Drugs Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Schizophrenia Drugs Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Vanda Pharmaceuticals
11.2.2. Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
11.2.3. Sumitomo Dainippon Pharma
11.2.4. Recordati Rare Diseases
11.2.5. Pfizer
11.2.6. Otsuka Pharmaceutical
11.2.7. Novartis
11.2.8. Johnson & Johnson (Janssen Pharmaceuticals)
11.2.9. Intra-Cellular Therapies
11.2.10. H. Lundbeck A/S
11.2.11. Eli Lilly and Company
11.2.12. Bristol Myers Squibb
11.2.13. AstraZeneca
11.2.14. Allergan (now part of AbbVie)
11.2.15. Alkermes plc
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
